Results 101 to 110 of about 10,095 (153)

Phase II trial of imatinib mesylate in patients with PDGFRA/B-negative hypereosinophilic syndrome. [PDF]

Br J Haematol
Kim DH, Kim S, Park S, Byun JM, Hong J, Shin DY, Kim I, Bang SM, Lee JO, Lee JY, Kim SA, Kim KH, Chung YJ, Jung SH, Koh Y, Yoon SS.   +15 more
europepmc   +1 more source

In Vivo Efficacy of Imatinib Mesylate, a Tyrosine Kinase Inhibitor, in the Treatment of Chemically Induced Dry Eye in Animal Models. [PDF]

Transl Vis Sci Technol, 2021
Baek YY, Sung B, Choi JS, Go HK, Kim DH, Hyon JY, You JC.   +6 more
europepmc   +1 more source

Erythema following imatinib mesylate [PDF]

British Journal of Haematology, 2003
Duncan, E, Raj, K, Mufti, G
openaire   +2 more sources

Effect of Imatinib Mesylate on the Ovarian Reserves of Female Patients with Chronic Myeloid Leukaemia. [PDF]

Indian J Hematol Blood Transfus
Satija T, Suri V, Arora A, Gupta N, Sachdeva N, Jain A, Malhotra P.   +6 more
europepmc   +1 more source

Imatinib mesylate in combination with pembrolizumab in patients with advanced KIT-mutant melanoma following progression on standard therapy: A phase I/II trial and study protocol. [PDF]

Medicine (Baltimore), 2021
Hirai I, Tanese K, Fukuda K, Fusumae T, Nakamura Y, Sato Y, Amagai M, Funakoshi T.   +7 more
europepmc   +1 more source

Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase. [PDF]

J Cancer Res Clin Oncol
Zhang J, Zhou S, Jiang S, He F, Tu Y, Hu H.   +5 more
europepmc   +1 more source

The association between FOXO3a rs4946936 gene polymorphism and the levels of FOXO3a among chronic granulocytic leukemia patients treated with imatinib mesylate. [PDF]

F1000Res, 2021
Wardhani SO, Susianti H, Rahayu P, Yueniwati YP, Fajar JK.   +4 more
europepmc   +1 more source

Imatinib Mesylate Causes Potential Cardiac Dysfunction in Patients With Chronic Myeloid Leukemia: the Results of a Case-control Study. [PDF]

Indian J Hematol Blood Transfus
Shankar G, Jain A, Gupta A, Jandial A, Varma N, Jain A, Prakash G, Khadwal A, Malhotra P.   +8 more
europepmc   +1 more source

Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate. [PDF]

Front Oncol, 2022
Siti Mariam I, Norhidayah R, Zulaikha AB, Nazihah MY, Rosline H, Kausar GA, Sarina S, Azlan H, Ankathil R.   +8 more
europepmc   +1 more source

Malignant rectal GIST managed with chemotherapy (Imatinib Mesylate): A case report and a comprehensive review. [PDF]

Radiol Case Rep
Bhusal A, Kc S, Yogi TN, Gupta RK, Kumar A, Khanal B, Katwal S, Neupane D, Lamichhane S, Bhagat R.   +9 more
europepmc   +1 more source